Madrigal Pharmaceuticals expanded its metabolic dysfunction-associated steatohepatitis (MASH) combination strategy by licensing an Arrowhead Pharmaceuticals small-interfering RNA therapy tied to a specific genetic mutation in fatty liver disease. The deal marks Madrigal’s fourth business development transaction in the past year and its second involving siRNA therapeutics. The company positioned the new asset as part of a broader effort to build a multi-mechanism regimen for MASH, following its existing siRNA and metabolic pipeline work. The licensing supports Madrigal’s focus on pairing complementary approaches to improve efficacy in patients with MASH. Details on timing and next clinical steps were not provided in the excerpt, but the transaction underscores continued investor and company appetite for genetically driven and RNA-silencing approaches in liver disease combinations.